Abstract
BackgroundJanus activated kinase (Jak) inhibition has shown clinical benefits in treatment of rheumatoid arthritis (RA). However, targeting all isoforms of Jak (Jak1, Jak2, Jak3, and Tyk2) may be associated with...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
